RESUMO
This study reports the follow-up after 22 years of 62 treated cases of Hodgkin's disease. Complete remission was obtained in 66% of cases versus 31% of incomplete remission and 3% of failures. Overall survival of patients ranged from 10 days to 48 months. Real event-free survival was difficult to estimate given that 40% were completely lost to follow-up. The most frequently encountered disorders were haematologic ones. The difficulties were directly linked to precarious socio-economic conditions for most patients.
Assuntos
Doença de Hodgkin/tratamento farmacológico , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Criança , Pré-Escolar , Côte d'Ivoire , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Indução de Remissão , Falha de TratamentoRESUMO
Une etude prospective sur la place du protocole cyclophosphamide-methotrexate-Aracytine (CMA) a ete entreprise d'octobre 1994 a fevrier 1999; sur 50 patients. Les resultats enregistres peuvent etre resumes en : remission complete; 76d'une duree moyenne de 24 mois; 5 cas de guerison a 5 ans; des survies allaient de 6 mois a 5 ans. Le pourcentage de deces a ete de 35. Les criteres de bonnes reponses therapeutiques ou protocole CMA; ont aussi ete determine.s
Assuntos
Linfoma de Burkitt , Protocolos Clínicos , CiclofosfamidaRESUMO
Les auteurs rapportent un etude epidemiologique des leucemies aigues allant d'octobre 1991 a fevrier 1999. La prevalence hospitaliere est de 23;86pour 1000 malades hospitalises. Il y avait 59;09de leucemies aigues lymphoblastique (LAL) et 40;91de leucemies aigues myeloide (LAM). L'age global etait de 29;13 ans et 60;60des patients etaient ages de 2 a 30 ans. Il a ete note une legere predominance masculine. Les hydrocarbures aromatiques (benzene et ses derives) sont fortement incrimines
Assuntos
Hidrocarbonetos Aromáticos , Leucemia/epidemiologia , Leucemia/etiologiaRESUMO
Out of 97320 hemoglobin electrophoreses performed in Abidjan between January 1976 and January 1991, all subjects with hemoglobin Lepore were isolated. This trait was identified by three techniques, i.e., alkaline pH electrophoresis, acid pH electrophoresis, and isoelectric focusing. Seventy-nine cases of hemoglobin Lepore were observed. All were heterozygotes with type HbA-Lepore (n = 54), HbC-Lepore (n = 8) or HbS Lepore (n = 17). Where heterozygosis A and C had clinically silent, heterozygosis Hb-S Lepore resulted in a moderate chronic hemolytic anemia and, in all cases, painful episodes similar to those observed during homozygote sickle-cell disease. However the onset of episodes was later and their occurrence was less frequent. On hemograms, the Lepore trait (HbA Lepore) appeared as a pseudo-polyglobulia with microcytosis; similar features were observed for heterozygosis HbC Lepore. Heterozygosis HbS Lepore caused moderate anemia (mean hemoglobin level: 10.66 g/dl) and microcytosis (MGV = 68.8 fl). The characteristics show that the clinical and hematological behavior of hemoglobin Lepore, a rare hemoglobin, is similar to heterozygous beta-thalassemia.
